Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

Top Stories Pentagon ending contracts Winning $389K win vanishes Delta passengers stranded La Niña is dead Diet and lung cancer risk ChatGPT AI action figure trend ...

Posted 2024-01-22T19:47:52Z - Updated 2024-01-22T20:50:07Z By David Arkin This article was written for our sponsor, North Carolina Biotechnology Center ...

Merck has been in north Durham since 2004. Last year, its Bull City campus produced 70.7 million doses, a figure the company expects to rise. “That number will continue to increase as we receive ...

Raleigh’s Verona Pharma acquired by Merck for $10 billion as maker of COPD treatment Ohtuvayre merges with pharmaceutical company with growing Durham, NC footprint ...

DURHAM – North Carolina’s unemployment rate is still hovering near 10 percent, but don’t tell that to pharmaceutical giant Merck & Co. By the end of this year, Merck will grow its Durham ...

DURHAM -- Merck & Co. Inc. said yesterday that it plans to spend about $300 million on a second expansion of its vaccine-manufacturing plant in Durham. The expansion will include up to 180 new jobs.